• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Transgender health and the impact of aging and menopause
Climacteric. 2023 Apr 3:1-7. doi: 10.1080/13697137.2023.2176217. Online ahead of print.ABSTRACTGender affirming hormone therapy (GAHT) is used by many transgender people to reduce gender incongruence and improve psychological functioning. As GAHT shares many similarities with menopausal hormone therapy, clinicians supporting people through menopause are ideally placed to manage GAHT. This narrative review provides an overview of transgender health and discusses long-term effects of GAHT to consider when managing transgender individuals across the lifespan. Menopause is less relevant for transgender individuals who take GAH...
Source: Climacteric - April 3, 2023 Category: Geriatrics Authors: A S Cheung B J Nolan S Zwickl Source Type: research

The role of medications in successful aging
Climacteric. 2021 May 12:1-8. doi: 10.1080/13697137.2021.1911991. Online ahead of print.ABSTRACTSuccessful aging includes good health and low levels of disability. To that end, primary prevention is far better than managing subsequent organ damage. When medication is needed to prevent or manage disease, the preferred choice should be associated with the greatest benefits and fewest adverse effects. Cardiovascular diseases are the leading cause of morbidity and mortality in postmenopausal women worldwide. Considering disease-adjusted life years, other leading causes are chronic obstructive pulmonary disease, diabetes mellit...
Source: Climacteric - May 12, 2021 Category: Geriatrics Authors: R D Langer Source Type: research

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovas...
Source: Osteoporosis International - July 7, 2020 Category: Orthopaedics Source Type: research

The 2017 hormone therapy position statement of The North American Menopause Society
The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by...
Source: Menopause - October 25, 2018 Category: OBGYN Tags: Commemorative Papers Source Type: research

Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study
Conclusions: Our results do not provide strong evidence for a protective association between postmenopausal HT use and AD or dementia, although we observed a reduced AD risk among those with long-term self-reported HT use.
Source: Neurology - March 12, 2017 Category: Neurology Authors: Imtiaz, B., Tuppurainen, M., Rikkonen, T., Kivipelto, M., Soininen, H., Kröger, H., Tolppanen, A.-M. Tags: Alzheimer's disease, Cohort studies ARTICLE Source Type: research

Study: Hormone replacement therapy may help improve women's heart health, overall survival
(Cedars-Sinai Medical Center) Hormone replacement therapy has long been controversial as studies have associated it with health benefits and risks. While some studies suggest that it lowers the risk of osteoporosis and improves some aspects of heart health, others link it to higher risk of cancer and stroke. Now, a new imaging study suggests that women using hormone replacement therapy to relieve menopause symptoms face a lower risk of death and show lower levels of atherosclerosis compared to women who do not use hormone therapy.
Source: EurekAlert! - Cancer - March 8, 2017 Category: Cancer & Oncology Source Type: news

The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Authors: Parish SJ, Gillespie JA Abstract This review describes the evolving role of oral hormone therapy (HT) for treating menopausal symptoms and preventing osteoporosis, focusing on conjugated estrogens/bazedoxifene (CE/BZA). Estrogens alleviate hot flushes and prevent bone loss associated with menopause. In nonhysterectomized women, a progestin should be added to estrogens to reduce the risk of endometrial cancer. Use of HT declined since the Women's Health Initiative (WHI) studies showed that HT does not prevent coronary heart disease (CHD) and that conjugated estrogens/medroxyprogesterone acetate increased th...
Source: Postgraduate Medicine - February 1, 2017 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Long-term hormone therapy for perimenopausal and postmenopausal women.
CONCLUSIONS: Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT, provided they do not have specific contraindications. HT may be unsuitable for some women, including those at increased risk of cardiovascular disease, increased risk of thromboembolic disease (such as those with obesity or a history of venous thrombosis) or increased risk of some types of cancer (such as breast cancer, in women with a uterus). The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well docu...
Source: Cochrane Database of Systematic Reviews - January 16, 2017 Category: Journals (General) Authors: Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J Tags: Cochrane Database Syst Rev Source Type: research

7 Tips To Lower Diabetes Risk in Menopause During the Holidays
By now, most people have been to a holiday party or two. Lots of food, lots of eggnog and other carb laden alcoholic beverages, and lots of grazing all day long on all the boxes of candy friends and business acquaintances sent to us. It's easy to gain the five pounds most people gain during the holidays, and in the process, raise your blood sugar or glucose levels too high. That's your body letting you know you have prediabetes (higher than normal but still below diabetes levels) or diabetes, and unless you take action soon, your body won't like it. Diabetes silently sneaks up on you and if untreated, slowly weakens your ...
Source: Healthy Living - The Huffington Post - December 23, 2016 Category: Consumer Health News Source Type: news

Hormone use and stroke
Publication date: Available online 14 March 2016 Source:Apollo Medicine Author(s): Pushpendra Nath Renjen, Dinesh M. Chaudhari, Mahir Meman Strokes are an important cause of disability and death among older women. Because many women use hormone therapy for the control of perimenopausal symptoms and to prevent osteoporosis after menopause, establishing whether such therapy has other health effects is of considerable clinical importance. Overall, 55% of strokes occur in women, and women account for nearly 60% of all stroke-related deaths. Women appear to be protected from heart disease and stroke before menopause. This ...
Source: Apollo Medicine - March 14, 2016 Category: Journals (General) Source Type: research

HRT increases ovarian cancer risk by small amount
Conclusion This systematic review and meta-analysis showed that ovarian cancer risk was significantly increased in current HRT users, even in those with less than five years of HRT use (the average was three years). In ex-users, risks decreased the longer ago HRT use had stopped, but risks during the first few years after stopping remained significant. Furthermore, about a decade after stopping, long-duration hormone therapy use (average nine years of HRT use), there still seemed to be a small excess risk. The review has a few limitations, however. The main one is that the review was heavily influenced by just two of t...
Source: NHS News Feed - February 13, 2015 Category: Consumer Health News Tags: Cancer Medication Older people Source Type: news

Managing menopause.
Authors: Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W Abstract OBJECTIVE: To provide updated guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor or urogenital symptoms and on considerations related to cardiovascular disease, breast cancer, urogynaecology, and sexuality. OUTCOMES: Lifestyle...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 2, 2014 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Pages: 1  2